H.C. Wainwright lowered the firm’s price target on TuHURA Biosciences (HURA) to $12 from $13 and keeps a Buy rating on the shares following the Q4 report.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HURA:
- TuHURA Biosciences Announces Acquisition of Kineta, Inc.
- TuHURA Biosciences Expands Board with New Appointment
- TuHURA Biosciences appoints Craig Tendler to board of directors
- Dollar General downgraded, Oracle upgraded: Wall Street’s top analyst calls
- TuHURA Biosciences initiated with a Buy at H.C. Wainwright
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue